Early clinical data from a CRISPR‑based in‑vivo therapy reduced LDL cholesterol and triglycerides dramatically in a small cohort, according to a preliminary report presented at a major cardiology meeting. The therapy, developed by CRISPR Therapeutics and tested in about 15 patients, produced profound lipid lowering after a single administration. Researchers and clinicians highlighted the promise of one‑time gene editing as a preventative strategy for cardiovascular disease, while warning that liver toxicities and long‑term safety remain unresolved. The trial’s scale is small and follow‑up limited; investigators called for expanded cohorts and detailed hepatic monitoring to define risk‑benefit profiles.